{'fraction_non_alphanumeric': 0.018121911037891267, 'fraction_numerical': 0.001098297638660077, 'mean_word_length': 5.239726027397261, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Elements: in this month's issue.

In this month’s issue there is another review in the virology/immunology miniseries. This time Prof Emery considers current understanding and future advances in the treatment of infection by cytomegalovirus (CMV). CMV is a common and highly successful pathogen. It is thought that over 70% of the human population has been infected with this virus. Apart from the ubiquitous nature of the virus, its potential for latency, particularly within the bone marrow, following initial infection is noteworthy. CMV is a highly dangerous infection in immuno-compromised individuals including neonates and those on immuno-suppressive drugs particularly post-organ transplantation. The virus plays an important role in the pathogenesis of various inflammatory processes and can contribute to premature death in ageing populations. As in other reviews within this series, the author considers the immunological response of the host to the viral infection, as an understanding of this process is essential for the development of more effective therapeutic measures. The review represents a useful update on current understanding of the role of CMV infection in both the T cell and non T cell immuno-compromised individual. Current control of viral replication is undertaken by means of anti-viral drugs which can be successfully used as prophylactic agents; however drugs currently in use have significant levels of toxicity. The other obvious therapeutic avenue would be immunisation of susceptible individuals. A number of vaccines are available which have varying levels of efficacy. However, much more still needs to be done with respect to the development of newer and safer antiviral agents along with effective vaccines to control this important infection. Recent advances in treatment of gout